Fig. 2.

CD166 is a marker of CSC-like population in A2780 ova-rian cancer cells. (A) We measured cell proliferation of unsorted A2780 cells, CD166⁺, and CD166⁻ cells by MTT assay at the indicated times. (B) We counted sphere numbers of unsorted A2780 cells, CD166⁺, and CD166⁻ cells on day 10. Migration (C) and cell adhesion (D) abilities of unsorted A2780 cells, CD166⁺, and CD166⁻ cells were measured. (E) We treated unsorted A2780 cells, CD166⁺, and CD166⁻ cells with increasing concentrations of doxorubicin and measured cell viability by MTT at 24 h. (F) Representative image of nude mice (upper image) and tumors (lower image) on day 38 after injection of CD166⁺ and CD166⁻ A2780 cells. (G) Tumor volumes at the indicated time points after injecting CD166⁺ and CD166⁻ cells were quantified at the indicated time points. (H) Tumor weights on day 38 after injecting CD166⁺ and CD166⁻ cells were measured. All results are presented as means ± SD (n = 5), *P < 0.05.